Regional Centre for Biotechnology

What Regional Centre for Biotechnology does

Regional Centre for Biotechnology (RCB) is an autonomous institution established in 2010 in Faridabad, India, operating under India's Department of Biotechnology to deliver education, training, and research in biotechnology. Its operations center on advanced biotechnology research, with a documented thematic focus on infectious disease — particularly dengue vaccine development and disease mechanism research — and it serves the scientific research community as its primary user base. RCB participates in major national and international research collaborations, including the COMBAT Indo-EU research alliance, Phase III clinical trials of the DengiAll dengue vaccine with the Indian Council of Medical Research and Panacea Biotec across 20 sites in 19 Indian states, and the regulatory ecosystem surrounding Takeda's Qdenga vaccine clearance in India.

The institution employs between 251 and 500 researchers and scientists and deploys advanced methodologies including single-cell sequencing, AI-powered analysis, and organ-on-chip models. Its stated functional direction includes the development of biomanufacturing hubs and biofoundries aimed at translating research outputs into industry applications. RCB hosted the inaugural BRIC Research Advisory Board meeting on March 27-28, 2026, positioning it as a coordinating node within the newly formed Biotechnology Research and Innovation Council, an apex body created by subsuming 14 autonomous institutes under the Department of Biotechnology.

RCB is a non-commercial government-affiliated research institution; pricing is not applicable and no revenue model, customer pricing, or commercial go-to-market mechanics are disclosed in the source data. Its distribution channels consist of scientific publications, research collaborations, and participation in international research alliances rather than commercial sales motions.

Name

Regional Centre for Biotechnology

Website

https://radheexchange.co

Company type

Private

Founded year

2010

Headcount range

251–500 employees

Short description

Regional Centre for Biotechnology is an autonomous Indian government-affiliated research institution in Faridabad that conducts advanced biotechnology research and training, serving the scientific community with a thematic focus on infectious disease and dengue vaccine development.

Ownership category

akta.pro rank

Product category

Biotechnology Research and Education

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Biotechnology research
• Biotechnology education
• Vaccine development
• Infectious disease research
• Translational biotechnology

Headquarters

HQ city

Faridabad

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Core offering

Regional Centre for Biotechnology is an autonomous institution providing postgraduate education, training, and advanced research in biotechnology. Its core research activities focus on understanding disease mechanisms and advancing vaccine development, with active programmes in dengue research leveraging technologies such as single-cell sequencing, AI-driven analysis, and organ-on-chip models. It also serves as a translational bridge through biomanufacturing hubs and biofoundries that move research outputs toward industry application.

Differentiator

Problem solved

Functional benefit

Products and services

• Biotechnology Postgraduate and Doctoral Education Programmes Postgraduate and doctoral academic programmes in biotechnology offered to students and researchers, centred on advanced biotechnology research training.
• Dengue Disease Mechanism and Vaccine Development Research Programme Collaborative research programme studying dengue disease mechanisms to improve vaccine development and treatment strategies, conducted in partnership with ICMR, Panacea Biotec, and Takeda.
• Biomanufacturing Hubs and Biofoundry Translational Platforms Translational platforms that enable conversion of biotechnology research outputs into industry-ready applications, supporting industrial and academic partners.
• BRIC Research Advisory Board Hosting and Coordination Coordination and hosting service for BRIC's apex research governance, bringing together leaders from 14 autonomous research institutes under the Department of Biotechnology.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core.

• Biotechnology Research and Innovation Council (BRIC)coreStrategic or Co-development Partner · 1 March 2026BRIC is an apex body formed by subsuming 14 autonomous institutes under the Department of Biotechnology. RCB hosted the inaugural meeting of BRIC's Research Advisory Board on March 27-28, 2026, where scientists and institutional leaders deliberated on transforming BRIC into a decentralized national biotechnology laboratory.
• COMBAT (Indo-EU Research Alliance)coreStrategic or Co-development PartnerCOMBAT is an Indo-EU research alliance focused on understanding disease mechanisms to improve vaccine development and treatment strategies. Scientists deploying breakthrough technologies including single-cell sequencing, AI, and organ-on-chip models are advancing dengue research through this alliance.
• Indian Council of Medical Research (ICMR)coreStrategic or Co-development PartnerICMR is conducting Phase III trials of the DengiAll single-dose recombinant dengue vaccine across 20 sites in 19 Indian states in collaboration with RCB research initiatives.
• Panacea BioteccoreStrategic or Co-development PartnerPanacea Biotec is conducting Phase III trials of the DengiAll single-dose recombinant dengue vaccine alongside ICMR across multiple sites in India, contributing to vaccine development efforts connected to RCB's research ecosystem.

Recent moves8 records

Expansion highlights4 records

Direct peers

• International Centre for Genetic Engineering and Biotechnology (ICGEB): UN-affiliated intergovernmental biotech research centre with labs in New Delhi, Trieste, and Cape Town. ICGEB is the closest international counterpart to RCB, conducting infectious disease and vaccine research with similar technology platforms and a public-sector mandate.
• Translational Health Science and Technology Institute (THSTI): Autonomous institute under India's Department of Biotechnology focused on translational and clinical research, including vaccine development. THSTI is one of the 14 institutes subsumed into BRIC and operates as a direct peer within the same governance ecosystem as RCB.
• National Institute of Immunology (NII): Autonomous research institute under India's Department of Biotechnology focused on immunology and infectious disease research. NII is another BRIC-member institute with a directly comparable mandate and operating model to RCB.
• National Centre for Biological Sciences (NCBS): Bengaluru-based research centre under the Tata Institute of Fundamental Research studying fundamental biology with strong infectious disease and biophysics programs. NCBS is a peer in scale, mandate, and Indian public-sector research standing.

Broad incumbents

• Pasteur Institute: Global reference institute for infectious disease research and vaccine development. Pasteur Institute is a much larger, established counterpart whose dengue, immunology, and translational programs model the trajectory RCB could follow.
• European Molecular Biology Laboratory (EMBL): Intergovernmental research organization in life sciences with member-state governance. EMBL's intergovernmental research model and advanced technology platforms (genomics, structural biology) parallel the BRIC consortium model RCB is helping to build.
• Broad Institute of MIT and Harvard: Large-scale genomics and biomedical research institute operating at the intersection of academic, clinical, and industry partners. Comparable to RCB in deploying single-cell sequencing, AI, and biofoundry infrastructure for translational research.
• Karolinska Institutet: Major medical university with deep infectious disease, vaccine, and translational research programs. Karolinska's blend of education, training, and research mirrors RCB's stated mandate, and its international alliances model the Indo-EU collaborations RCB pursues via COMBAT.
• Wellcome Sanger Institute: Leading genomics and bioinformatics research institute, with major programs in infectious disease surveillance and pathogen genomics. Sanger's platform-driven approach to large-scale sequencing and global health partnerships is comparable to RCB's high-end technology stack.

Regional players

• Genome Institute of Singapore (GIS, A*STAR): National genomics and infectious disease research institute under Singapore's A*STAR. GIS operates in Asia with a comparable mandate around genomics, single-cell analysis, and translational infectious disease research, making it a strong regional peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/unescorcb
• Facebookfacebook.com/unescorcb
• LinkedInlinkedin.com/company/regional-centre-for-biotechnology

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regional Centre for Biotechnology